Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Valeria Foresta"'
Autor:
Francesca Lisi, B. Ottanelli, Gloriano Moneti, Stefano Milani, Elisabetta Ceni, Tommaso Mello, Giuseppe Pieraccini, Laura Cioni, F. Buccoliero, Guido Mastrobuoni, Mirko Tarocchi, Andrea Galli, Simone Polvani, Calogero Surrenti, Valeria Foresta
Publikováno v:
Hepatology. 52:493-505
UNLABELLED Antidiabetic thiazolidinediones (TZD) have in vitro antiproliferative effect in epithelial cancers, including hepatocellular carcinoma (HCC). The effective anticancer properties and the underlying molecular mechanisms of these drugs in viv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f886231205782abca6c0e901f8d2c693
https://doi.org/10.1002/hep.23669
https://doi.org/10.1002/hep.23669
Autor:
Alessandro Mordini, Ivano Bertini, Massimo Calamante, Alessandro Quattrone, Elisabetta Ceni, Massimo D'Amico, Valeria Foresta, Andrea Galli, Simone Polvani, Claudio Luchinat
Publikováno v:
Gastroenterology (N.Y.N.Y., 1943) 140 (2011): 709–720. doi:10.1053/j.gastro.2010.10.050
info:cnr-pdr/source/autori:Polvani, Simone; Calamante, Massimo; Foresta, Valeria; Ceni, Elisabetta; Mordini, Alessandro; Quattrone, Alessandro; D'Amico, Massimo; Luchinat, Claudio; Bertini, Ivano; Galli, Andrea/titolo:Acycloguanosyl 5?-thymidyltriphosphate, a thymidine analogue prodrug activated by telomerase, reduces pancreatic tumor growth in mice/doi:10.1053%2Fj.gastro.2010.10.050/rivista:Gastroenterology (N.Y.N.Y., 1943)/anno:2011/pagina_da:709/pagina_a:720/intervallo_pagine:709–720/volume:140
info:cnr-pdr/source/autori:Polvani, Simone; Calamante, Massimo; Foresta, Valeria; Ceni, Elisabetta; Mordini, Alessandro; Quattrone, Alessandro; D'Amico, Massimo; Luchinat, Claudio; Bertini, Ivano; Galli, Andrea/titolo:Acycloguanosyl 5?-thymidyltriphosphate, a thymidine analogue prodrug activated by telomerase, reduces pancreatic tumor growth in mice/doi:10.1053%2Fj.gastro.2010.10.050/rivista:Gastroenterology (N.Y.N.Y., 1943)/anno:2011/pagina_da:709/pagina_a:720/intervallo_pagine:709–720/volume:140
Background & Aims Gemcitabine is the standard of care for metastatic and nonresectable pancreatic tumors. Phase II and III trials have not demonstrated efficacy of recently developed reagents, compared with gemcitabine alone; new chemotherapic agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d937d6678337b6bcc45988957752cde
https://doi.org/10.1053/j.gastro.2010.10.050
https://doi.org/10.1053/j.gastro.2010.10.050